Syndax Pharmaceuticals Inc (SNDX)
22.05
+0.19
(+0.87%)
USD |
NASDAQ |
May 03, 16:00
22.04
0.00 (0.00%)
After-Hours: 20:00
Syndax Pharmaceuticals Cash from Financing (Quarterly): 258.48M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 258.48M |
| September 30, 2023 | 1.851M |
| June 30, 2023 | 1.324M |
| March 31, 2023 | 2.474M |
| December 31, 2022 | 163.50M |
| September 30, 2022 | -13.52M |
| June 30, 2022 | 21.72M |
| March 31, 2022 | 0.557M |
| December 31, 2021 | 109.78M |
| September 30, 2021 | 1.705M |
| June 30, 2021 | 6.02M |
| March 31, 2021 | 0.96M |
| December 31, 2020 | 138.66M |
| September 30, 2020 | 1.767M |
| June 30, 2020 | 109.00M |
| March 31, 2020 | 55.00M |
| December 31, 2019 | 0.058M |
| September 30, 2019 | 0.08M |
| June 30, 2019 | 0.006M |
| March 31, 2019 | 28.43M |
| December 31, 2018 | 6.145M |
| September 30, 2018 | 9.462M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.089M |
| March 31, 2018 | 0.033M |
| December 31, 2017 | 25.61M |
| September 30, 2017 | 1.004M |
| June 30, 2017 | 48.99M |
| March 31, 2017 | 0.117M |
| December 31, 2016 | 0.176M |
| September 30, 2016 | 1.71M |
| June 30, 2016 | -1.232M |
| March 31, 2016 | 53.55M |
| December 31, 2015 | -9.182M |
| September 30, 2015 | 60.06M |
| June 30, 2015 | 18.68M |
| March 31, 2015 | 7.712M |
| December 31, 2014 | 3.995M |
| September 30, 2014 | 9.511M |
| June 30, 2014 | -0.892M |
| March 31, 2014 | -0.204M |
| December 31, 2013 | 11.88M |
| September 30, 2013 | 6.475M |
| June 30, 2013 | 1.005M |
| March 31, 2013 | 1.534M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-13.52M
Minimum
Sep 2022
258.48M
Maximum
Dec 2023
45.23M
Average
1.851M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| SpringWorks Therapeutics Inc | -0.552M |
| Alnylam Pharmaceuticals Inc | 28.91M |
| Geron Corp | 147.80M |
| Ionis Pharmaceuticals Inc | 40.72M |
| Madrigal Pharmaceuticals Inc | 479.92M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -41.35M |
| Cash from Investing (Quarterly) | -16.29M |
| Free Cash Flow | -160.60M |
| Free Cash Flow Per Share (Quarterly) | -0.57 |
| Free Cash Flow Yield | -10.35% |